ID   MPIP2_HUMAN             Reviewed;         580 AA.
AC   P30305; D3DVY1; D3DVY2; D3DVY3; D3DVY4; O43551; Q13971; Q5JX77; Q6RSS1;
AC   Q9BRA6;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   27-MAY-2002, sequence version 2.
DT   18-JUN-2025, entry version 232.
DE   RecName: Full=M-phase inducer phosphatase 2;
DE            EC=3.1.3.48 {ECO:0000305|PubMed:20360007};
DE   AltName: Full=Dual specificity phosphatase Cdc25B;
GN   Name=CDC25B; Synonyms=CDC25HU2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=1836978; DOI=10.1016/0092-8674(91)90294-9;
RA   Galaktionov K.I., Beach D.;
RT   "Specific activation of cdc25 tyrosine phosphatases by B-type cyclins:
RT   evidence for multiple roles of mitotic cyclins.";
RL   Cell 67:1181-1194(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1662986;
RA   Nagata A., Igarashi M., Jinno S., Suto K., Okayama H.;
RT   "An additional homolog of the fission yeast cdc25+ gene occurs in humans
RT   and is highly expressed in some cancer cells.";
RL   New Biol. 3:959-968(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=9188863; DOI=10.1038/sj.onc.1201063;
RA   Baldin V., Cans C., Superti-Furga G., Docommun B.;
RT   "Alternative splicing of the human CDC25B tyrosine phosphatase. Possible
RT   implications for growth control?";
RL   Oncogene 14:2485-2495(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-548.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-352 (ISOFORMS 2 AND 3).
RA   McCormack A.K., DeSouza C.C.P.C., Tonks I.D., Clark J.M., Forrest A.R.R.,
RA   Hayward N.K., Ellem K.A.O., Gabrielli B.G.;
RT   "Alternative splicing of cdc25B.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PHOSPHORYLATION AT SER-323 AND SER-375, AND INTERACTION WITH MAPK14 AND
RP   14-3-3 PROTEINS.
RX   PubMed=11333986; DOI=10.1038/35075107;
RA   Bulavin D.V., Higashimoto Y., Popoff I.J., Gaarde W.A., Basrur V.,
RA   Potapova O., Appella E., Fornace A.J. Jr.;
RT   "Initiation of a G2/M checkpoint after ultraviolet radiation requires p38
RT   kinase.";
RL   Nature 411:102-107(2001).
RN   [10]
RP   PHOSPHORYLATION AT SER-323.
RX   PubMed=12400006; DOI=10.1038/sj.onc.1205870;
RA   Davezac N., Baldin V., Blot J., Ducommun B., Tassan J.P.;
RT   "Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a
RT   potential role for pEg3 in cell cycle regulation.";
RL   Oncogene 21:7630-7641(2002).
RN   [11]
RP   PHOSPHORYLATION AT SER-375.
RC   TISSUE=Testis;
RX   PubMed=15150265; DOI=10.1074/jbc.m404728200;
RA   Lu R., Niida H., Nakanishi M.;
RT   "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint
RT   function.";
RL   J. Biol. Chem. 279:31164-31170(2004).
RN   [12]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-353 BY AURKA.
RX   PubMed=15128871; DOI=10.1242/jcs.01108;
RA   Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C.,
RA   Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B.,
RA   Prigent C., Ducommun B.;
RT   "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the
RT   G2-M transition.";
RL   J. Cell Sci. 117:2523-2531(2004).
RN   [13]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY CHEK1.
RX   PubMed=15311285; DOI=10.1038/ncb1165;
RA   Kraemer A., Mailand N., Lukas C., Syljuaesen R.G., Wilkinson C.J.,
RA   Nigg E.A., Bartek J., Lukas J.;
RT   "Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1
RT   kinase.";
RL   Nat. Cell Biol. 6:884-891(2004).
RN   [14]
RP   PHOSPHORYLATION AT SER-169, AND SUBCELLULAR LOCATION.
RX   PubMed=15908796; DOI=10.4161/cc.4.6.1716;
RA   Mirey G., Chartrain I., Froment C., Quaranta M., Bouche J.P., Monsarrat B.,
RA   Tassan J.P., Ducommun B.;
RT   "CDC25B phosphorylated by pEg3 localizes to the centrosome and the spindle
RT   poles at mitosis.";
RL   Cell Cycle 4:806-811(2005).
RN   [15]
RP   PHOSPHORYLATION AT SER-323 BY MAPKAPK2.
RX   PubMed=15629715; DOI=10.1016/j.molcel.2004.11.021;
RA   Manke I.A., Nguyen A., Lim D., Stewart M.Q., Elia A.E., Yaffe M.B.;
RT   "MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M
RT   transition and S phase progression in response to UV irradiation.";
RL   Mol. Cell 17:37-48(2005).
RN   [16]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=17332740; DOI=10.1038/sj.emboj.7601637;
RA   Schmidt A., Durgan J., Magalhaes A., Hall A.;
RT   "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from
RT   cytokinesis.";
RL   EMBO J. 26:1624-1636(2007).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   FUNCTION.
RX   PubMed=20360007; DOI=10.1074/jbc.m109.096552;
RA   Timofeev O., Cizmecioglu O., Settele F., Kempf T., Hoffmann I.;
RT   "Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at
RT   the G2/M transition.";
RL   J. Biol. Chem. 285:16978-16990(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; SER-323; SER-353;
RP   SER-375; SER-470 AND SER-563, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 370-580.
RX   PubMed=10543950; DOI=10.1006/jmbi.1999.3168;
RA   Reynolds R.A., Yem A.W., Wolfe C.L., Deibel M.R. Jr., Chidester C.G.,
RA   Watenpaugh K.D.;
RT   "Crystal structure of the catalytic subunit of Cdc25B required for G2/M
RT   phase transition of the cell cycle.";
RL   J. Mol. Biol. 293:559-568(1999).
CC   -!- FUNCTION: Tyrosine protein phosphatase which functions as a dosage-
CC       dependent inducer of mitotic progression (PubMed:1836978,
CC       PubMed:20360007). Directly dephosphorylates CDK1 and stimulates its
CC       kinase activity (PubMed:20360007). Required for G2/M phases of the cell
CC       cycle progression and abscission during cytokinesis in a ECT2-dependent
CC       manner (PubMed:17332740). The three isoforms seem to have a different
CC       level of activity (PubMed:1836978). {ECO:0000269|PubMed:17332740,
CC       ECO:0000269|PubMed:1836978, ECO:0000269|PubMed:20360007}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:61978; EC=3.1.3.48;
CC         Evidence={ECO:0000305|PubMed:20360007};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685;
CC         Evidence={ECO:0000305|PubMed:20360007};
CC   -!- ACTIVITY REGULATION: Stimulated by B-type cyclins.
CC       {ECO:0000269|PubMed:1836978}.
CC   -!- SUBUNIT: Interacts with MAPK14 and 14-3-3 proteins.
CC       {ECO:0000269|PubMed:11333986}.
CC   -!- INTERACTION:
CC       P30305; P61289: PSME3; NbExp=3; IntAct=EBI-1051746, EBI-355546;
CC       P30305; P31947: SFN; NbExp=2; IntAct=EBI-1051746, EBI-476295;
CC       P30305; P31946: YWHAB; NbExp=6; IntAct=EBI-1051746, EBI-359815;
CC       P30305; P62258: YWHAE; NbExp=5; IntAct=EBI-1051746, EBI-356498;
CC       P30305; P61981: YWHAG; NbExp=5; IntAct=EBI-1051746, EBI-359832;
CC       P30305; Q04917: YWHAH; NbExp=7; IntAct=EBI-1051746, EBI-306940;
CC       P30305; P63104: YWHAZ; NbExp=9; IntAct=EBI-1051746, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:15128871,
CC       ECO:0000269|PubMed:15311285, ECO:0000269|PubMed:15908796}. Cytoplasm,
CC       cytoskeleton, spindle pole {ECO:0000269|PubMed:15908796}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=3; Synonyms=CDC25B3;
CC         IsoId=P30305-1; Sequence=Displayed;
CC       Name=1; Synonyms=CDC25B1;
CC         IsoId=P30305-2; Sequence=VSP_000861;
CC       Name=2; Synonyms=CDC25B2;
CC         IsoId=P30305-3; Sequence=VSP_000862;
CC       Name=4;
CC         IsoId=P30305-4; Sequence=VSP_000861, VSP_012587;
CC   -!- PTM: Phosphorylated by BRSK1 in vitro. Phosphorylated by CHEK1, which
CC       inhibits the activity of this protein. Phosphorylation at Ser-353 by
CC       AURKA might locally participate in the control of the onset of mitosis.
CC       Phosphorylation by MELK at Ser-169 promotes localization to the
CC       centrosome and the spindle poles during mitosis. Phosphorylation at
CC       Ser-323 and Ser-375 by MAPK14 is required for binding to 14-3-3
CC       proteins. {ECO:0000269|PubMed:11333986, ECO:0000269|PubMed:12400006,
CC       ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15150265,
CC       ECO:0000269|PubMed:15311285, ECO:0000269|PubMed:15629715,
CC       ECO:0000269|PubMed:15908796, ECO:0000269|PubMed:17332740}.
CC   -!- SIMILARITY: Belongs to the MPI phosphatase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M81934; AAA58416.1; -; mRNA.
DR   EMBL; S78187; AAB21139.1; -; mRNA.
DR   EMBL; X96436; CAA65303.1; -; Genomic_DNA.
DR   EMBL; Z68092; CAA92108.1; -; mRNA.
DR   EMBL; AY494082; AAR26469.1; -; Genomic_DNA.
DR   EMBL; AL109804; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10491.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10492.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10493.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10494.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10496.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10497.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10498.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10499.1; -; Genomic_DNA.
DR   EMBL; BC006395; AAH06395.1; -; mRNA.
DR   EMBL; BC009953; AAH09953.1; -; mRNA.
DR   EMBL; BC051711; AAH51711.1; -; mRNA.
DR   EMBL; AF036233; AAB94622.1; -; Genomic_DNA.
DR   EMBL; AF036233; AAB94624.1; -; Genomic_DNA.
DR   CCDS; CCDS13065.1; -. [P30305-2]
DR   CCDS; CCDS13066.1; -. [P30305-3]
DR   CCDS; CCDS13067.1; -. [P30305-1]
DR   PIR; B41648; B41648.
DR   RefSeq; NP_001274448.1; NM_001287519.1.
DR   RefSeq; NP_001274453.1; NM_001287524.1.
DR   RefSeq; NP_004349.1; NM_004358.5. [P30305-2]
DR   RefSeq; NP_068658.1; NM_021872.4. [P30305-3]
DR   RefSeq; NP_068659.1; NM_021873.4. [P30305-1]
DR   PDB; 1CWR; X-ray; 2.10 A; A=370-580.
DR   PDB; 1CWS; X-ray; 2.00 A; A=370-580.
DR   PDB; 1CWT; X-ray; 2.30 A; A=388-565.
DR   PDB; 1QB0; X-ray; 1.91 A; A=370-580.
DR   PDB; 1YM9; X-ray; 2.00 A; A=391-564.
DR   PDB; 1YMD; X-ray; 1.70 A; A=391-564.
DR   PDB; 1YMK; X-ray; 1.70 A; A=391-564.
DR   PDB; 1YML; X-ray; 1.70 A; A=391-564.
DR   PDB; 1YS0; X-ray; 2.00 A; A=391-564.
DR   PDB; 2A2K; X-ray; 1.52 A; A=391-564.
DR   PDB; 2IFD; X-ray; 2.00 A; A=391-564.
DR   PDB; 2IFV; X-ray; 1.60 A; A=391-564.
DR   PDB; 2UZQ; X-ray; 2.38 A; A/B/C/D/E/F=391-580.
DR   PDB; 3FQT; X-ray; 1.80 A; C=38-46.
DR   PDB; 3FQU; X-ray; 1.80 A; C=38-46.
DR   PDB; 4WH7; X-ray; 1.62 A; A=386-565.
DR   PDB; 4WH9; X-ray; 1.50 A; A=386-565.
DR   PDBsum; 1CWR; -.
DR   PDBsum; 1CWS; -.
DR   PDBsum; 1CWT; -.
DR   PDBsum; 1QB0; -.
DR   PDBsum; 1YM9; -.
DR   PDBsum; 1YMD; -.
DR   PDBsum; 1YMK; -.
DR   PDBsum; 1YML; -.
DR   PDBsum; 1YS0; -.
DR   PDBsum; 2A2K; -.
DR   PDBsum; 2IFD; -.
DR   PDBsum; 2IFV; -.
DR   PDBsum; 2UZQ; -.
DR   PDBsum; 3FQT; -.
DR   PDBsum; 3FQU; -.
DR   PDBsum; 4WH7; -.
DR   PDBsum; 4WH9; -.
DR   AlphaFoldDB; P30305; -.
DR   SMR; P30305; -.
DR   BioGRID; 107429; 132.
DR   CORUM; P30305; -.
DR   DIP; DIP-323N; -.
DR   ELM; P30305; -.
DR   FunCoup; P30305; 1723.
DR   IntAct; P30305; 21.
DR   MINT; P30305; -.
DR   STRING; 9606.ENSP00000245960; -.
DR   BindingDB; P30305; -.
DR   ChEMBL; CHEMBL4804; -.
DR   DrugBank; DB03661; L-cysteic acid.
DR   DrugBank; DB03345; Mercaptoethanol.
DR   DrugBank; DB01915; S-Hydroxycysteine.
DR   DrugCentral; P30305; -.
DR   DEPOD; CDC25B; -.
DR   GlyGen; P30305; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P30305; -.
DR   PhosphoSitePlus; P30305; -.
DR   BioMuta; CDC25B; -.
DR   DMDM; 21264471; -.
DR   CPTAC; CPTAC-1253; -.
DR   CPTAC; CPTAC-1254; -.
DR   CPTAC; CPTAC-5903; -.
DR   CPTAC; CPTAC-5904; -.
DR   CPTAC; CPTAC-5905; -.
DR   jPOST; P30305; -.
DR   MassIVE; P30305; -.
DR   PaxDb; 9606-ENSP00000245960; -.
DR   PeptideAtlas; P30305; -.
DR   ProteomicsDB; 54654; -. [P30305-1]
DR   ProteomicsDB; 54655; -. [P30305-2]
DR   ProteomicsDB; 54656; -. [P30305-3]
DR   ProteomicsDB; 54657; -. [P30305-4]
DR   Pumba; P30305; -.
DR   Antibodypedia; 3625; 952 antibodies from 40 providers.
DR   CPTC; P30305; 2 antibodies.
DR   DNASU; 994; -.
DR   Ensembl; ENST00000245960.10; ENSP00000245960.5; ENSG00000101224.18. [P30305-1]
DR   Ensembl; ENST00000340833.4; ENSP00000339170.4; ENSG00000101224.18. [P30305-3]
DR   Ensembl; ENST00000439880.6; ENSP00000405972.2; ENSG00000101224.18. [P30305-2]
DR   GeneID; 994; -.
DR   KEGG; hsa:994; -.
DR   MANE-Select; ENST00000245960.10; ENSP00000245960.5; NM_021873.4; NP_068659.1.
DR   UCSC; uc002wjn.5; human. [P30305-1]
DR   AGR; HGNC:1726; -.
DR   CTD; 994; -.
DR   DisGeNET; 994; -.
DR   GeneCards; CDC25B; -.
DR   HGNC; HGNC:1726; CDC25B.
DR   HPA; ENSG00000101224; Low tissue specificity.
DR   MIM; 116949; gene.
DR   OpenTargets; ENSG00000101224; -.
DR   VEuPathDB; HostDB:ENSG00000101224; -.
DR   eggNOG; KOG3772; Eukaryota.
DR   GeneTree; ENSGT00940000158524; -.
DR   InParanoid; P30305; -.
DR   OMA; MHSKCRR; -.
DR   OrthoDB; 26523at2759; -.
DR   PAN-GO; P30305; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P30305; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   PathwayCommons; P30305; -.
DR   Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   Reactome; R-HSA-9825892; Regulation of MITF-M-dependent genes involved in cell cycle and proliferation.
DR   SignaLink; P30305; -.
DR   SIGNOR; P30305; -.
DR   BioGRID-ORCS; 994; 156 hits in 1183 CRISPR screens.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   ChiTaRS; CDC25B; human.
DR   EvolutionaryTrace; P30305; -.
DR   GeneWiki; CDC25B; -.
DR   GenomeRNAi; 994; -.
DR   Pharos; P30305; Tchem.
DR   PRO; PR:P30305; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P30305; protein.
DR   Bgee; ENSG00000101224; Expressed in granulocyte and 193 other cell types or tissues.
DR   ExpressionAtlas; P30305; baseline and differential.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0000922; C:spindle pole; IDA:UniProtKB.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IBA:GO_Central.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007144; P:female meiosis I; IEA:Ensembl.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:UniProtKB.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0110032; P:positive regulation of G2/MI transition of meiotic cell cycle; IBA:GO_Central.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   CDD; cd01530; Cdc25; 1.
DR   FunFam; 3.40.250.10:FF:000006; M-phase inducer phosphatase 2; 1.
DR   Gene3D; 3.40.250.10; Rhodanese-like domain; 1.
DR   InterPro; IPR000751; MPI_Phosphatase.
DR   InterPro; IPR001763; Rhodanese-like_dom.
DR   InterPro; IPR036873; Rhodanese-like_dom_sf.
DR   PANTHER; PTHR10828:SF48; M-PHASE INDUCER PHOSPHATASE 2; 1.
DR   PANTHER; PTHR10828; M-PHASE INDUCER PHOSPHATASE DUAL SPECIFICITY PHOSPHATASE CDC25; 1.
DR   Pfam; PF06617; M-inducer_phosp; 1.
DR   Pfam; PF00581; Rhodanese; 1.
DR   PRINTS; PR00716; MPIPHPHTASE.
DR   SMART; SM00450; RHOD; 1.
DR   SUPFAM; SSF52821; Rhodanese/Cell cycle control phosphatase; 1.
DR   PROSITE; PS50206; RHODANESE_3; 1.
DR   neXtProt; NX_P30305; -.
DR   PharmGKB; PA26260; -.
DR   TreeFam; TF101056; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell division; Cytoplasm;
KW   Cytoskeleton; Hydrolase; Mitosis; Phosphoprotein; Protein phosphatase;
KW   Proteomics identification; Reference proteome.
FT   CHAIN           1..580
FT                   /note="M-phase inducer phosphatase 2"
FT                   /id="PRO_0000198644"
FT   DOMAIN          431..538
FT                   /note="Rhodanese"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00173"
FT   REGION          1..24
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          89..117
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          165..196
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          331..370
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        89..107
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        334..344
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        487
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48966"
FT   MOD_RES         169
FT                   /note="Phosphoserine; by MELK"
FT                   /evidence="ECO:0000269|PubMed:15908796"
FT   MOD_RES         249
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         323
FT                   /note="Phosphoserine; by MELK and MAPK14"
FT                   /evidence="ECO:0000269|PubMed:11333986,
FT                   ECO:0000269|PubMed:12400006, ECO:0000269|PubMed:15629715,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         353
FT                   /note="Phosphoserine; by AURKA"
FT                   /evidence="ECO:0000269|PubMed:15128871,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         375
FT                   /note="Phosphoserine; by BRSK1 and MAPK14"
FT                   /evidence="ECO:0000269|PubMed:11333986,
FT                   ECO:0000269|PubMed:15150265, ECO:0007744|PubMed:23186163"
FT   MOD_RES         470
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         563
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         68..81
FT                   /note="Missing (in isoform 1 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:1662986,
FT                   ECO:0000303|PubMed:1836978"
FT                   /id="VSP_000861"
FT   VAR_SEQ         154..194
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9188863"
FT                   /id="VSP_000862"
FT   VAR_SEQ         194
FT                   /note="N -> NVRFWKAGVGALREEEGACWGGSLACEDPPLPSWLQ (in
FT                   isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_012587"
FT   VARIANT         548
FT                   /note="E -> K (in dbSNP:rs11570019)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_020933"
FT   CONFLICT        575
FT                   /note="S -> D (in Ref. 2; AAB21139)"
FT                   /evidence="ECO:0000305"
FT   STRAND          396..399
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   HELIX           417..424
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   TURN            425..431
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   STRAND          432..439
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   HELIX           443..447
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   HELIX           460..468
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   TURN            469..471
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   STRAND          479..486
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   STRAND          488..492
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   HELIX           493..508
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   STRAND          519..522
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   HELIX           525..532
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   HELIX           534..536
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   STRAND          537..540
FT                   /evidence="ECO:0007829|PDB:4WH9"
FT   HELIX           548..550
FT                   /evidence="ECO:0007829|PDB:2A2K"
FT   HELIX           551..558
FT                   /evidence="ECO:0007829|PDB:4WH9"
SQ   SEQUENCE   580 AA;  64987 MW;  EDE24B0E84AC1BE3 CRC64;
     MEVPQPEPAP GSALSPAGVC GGAQRPGHLP GLLLGSHGLL GSPVRAAASS PVTTLTQTMH
     DLAGLGSETP KSQVGTLLFR SRSRLTHLSL SRRASESSLS SESSESSDAG LCMDSPSPMD
     PHMAEQTFEQ AIQAASRIIR NEQFAIRRFQ SMPVRLLGHS PVLRNITNSQ APDGRRKSEA
     GSGAASSSGE DKENDGFVFK MPWKPTHPSS THALAEWASR REAFAQRPSS APDLMCLSPD
     RKMEVEELSP LALGRFSLTP AEGDTEEDDG FVDILESDLK DDDAVPPGME SLISAPLVKT
     LEKEEEKDLV MYSKCQRLFR SPSMPCSVIR PILKRLERPQ DRDTPVQNKR RRSVTPPEEQ
     QEAEEPKARV LRSKSLCHDE IENLLDSDHR ELIGDYSKAF LLQTVDGKHQ DLKYISPETM
     VALLTGKFSN IVDKFVIVDC RYPYEYEGGH IKTAVNLPLE RDAESFLLKS PIAPCSLDKR
     VILIFHCEFS SERGPRMCRF IRERDRAVND YPSLYYPEMY ILKGGYKEFF PQHPNFCEPQ
     DYRPMNHEAF KDELKTFRLK TRSWAGERSR RELCSRLQDQ
//
